1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Drugs In Development, 2022, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 6, 1, 27 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Fragile X Syndrome - Overview
- Fragile X Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Fragile X Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fragile X Syndrome - Companies Involved in Therapeutics Development
- Fragile X Syndrome - Drug Profiles
- Fragile X Syndrome - Dormant Projects
- Fragile X Syndrome - Discontinued Products
- Fragile X Syndrome - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Fragile X Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Fragile X Syndrome - Pipeline by Actinogen Medical Ltd, 2022
- Fragile X Syndrome - Pipeline by Allos Pharma Inc, 2022
- Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, 2022
- Fragile X Syndrome - Pipeline by Anima Biotech Inc, 2022
- Fragile X Syndrome - Pipeline by Astellas Pharma Inc, 2022
- Fragile X Syndrome - Pipeline by Autifony Therapeutics Ltd, 2022
- Fragile X Syndrome - Pipeline by Avekshan LLC, 2022
- Fragile X Syndrome - Pipeline by Cognosetta Inc, 2022
- Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, 2022
- Fragile X Syndrome - Pipeline by Connecta Therapeutics SL, 2022
- Fragile X Syndrome - Pipeline by DRI Biosciences Corp, 2022
- Fragile X Syndrome - Pipeline by Epigen Biosciences Inc, 2022
- Fragile X Syndrome - Pipeline by GEXVal Inc, 2022
- Fragile X Syndrome - Pipeline by GSK plc, 2022
- Fragile X Syndrome - Pipeline by Healx Ltd, 2022
- Fragile X Syndrome - Pipeline by Hua Medicine Shanghai Ltd, 2022
- Fragile X Syndrome - Pipeline by Jazz Pharmaceuticals Plc, 2022
- Fragile X Syndrome - Pipeline by Lysogene SAS, 2022
- Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, 2022
- Fragile X Syndrome - Pipeline by Neurochlore, 2022
- Fragile X Syndrome - Pipeline by NeuroNascent Inc, 2022
- Fragile X Syndrome - Pipeline by Novartis AG, 2022
- Fragile X Syndrome - Pipeline by Paxmedica Inc, 2022
- Fragile X Syndrome - Pipeline by Pilz Bioscience Corp, 2022
- Fragile X Syndrome - Pipeline by Prilenia Therapeutics Development Ltd, 2022
- Fragile X Syndrome - Pipeline by Prous Institute for Biomedical Research SA, 2022
- Fragile X Syndrome - Pipeline by Puretech Health Plc, 2022
- Fragile X Syndrome - Pipeline by Quris Technologies Ltd, 2022
- Fragile X Syndrome - Pipeline by Recursion Pharmaceuticals Inc, 2022
- Fragile X Syndrome - Pipeline by RespireRx Pharmaceuticals Inc, 2022
- Fragile X Syndrome - Pipeline by Sentinel Oncology Ltd, 2022
- Fragile X Syndrome - Pipeline by Synaptogenix Inc, 2022
- Fragile X Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Fragile X Syndrome - Pipeline by Taysha Gene Therapies Inc, 2022
- Fragile X Syndrome - Pipeline by Tetra Therapeutics, 2022
- Fragile X Syndrome - Pipeline by Triplet Therapeutics Inc, 2022
- Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, 2022
- Fragile X Syndrome - Dormant Projects, 2022
- Fragile X Syndrome - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Fragile X Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Actinogen Medical Ltd
- Allos Pharma Inc
- Anavex Life Sciences Corp
- Anima Biotech Inc
- Astellas Pharma Inc
- Autifony Therapeutics Ltd
- Avekshan LLC
- Cognosetta Inc
- Confluence Pharmaceuticals LLC
- Connecta Therapeutics SL
- DRI Biosciences Corp
- Epigen Biosciences Inc
- GEXVal Inc
- GSK plc
- Healx Ltd
- Hua Medicine Shanghai Ltd
- Jazz Pharmaceuticals Plc
- Lysogene SAS
- Neuren Pharmaceuticals Ltd
- Neurochlore
- NeuroNascent Inc
- Novartis AG
- Paxmedica Inc
- Pilz Bioscience Corp
- Prilenia Therapeutics Development Ltd
- Prous Institute for Biomedical Research SA
- Puretech Health Plc
- Quris Technologies Ltd
- Recursion Pharmaceuticals Inc
- RespireRx Pharmaceuticals Inc
- Sentinel Oncology Ltd
- Synaptogenix Inc
- Takeda Pharmaceutical Co Ltd
- Taysha Gene Therapies Inc
- Tetra Therapeutics
- Triplet Therapeutics Inc
- Zynerba Pharmaceuticals Inc
